Available online 14 November 2023
Chronic immune diseases mainly include autoimmune and inflammatory diseases. Managing chronic inflammatory and autoimmune diseases has become a significant public health concern, and therapeutic advancements over the past 50 years have been substantial. As therapeutic tools continue to multiply, the challenge now lies in providing each patient with personalized care tailored to the specifics of their condition, ushering in the era of personalized medicine. Precise and holistic imaging is essential in this context to comprehensively map the inflammatory processes in each patient, identify prognostic factors, and monitor treatment responses and complications. Imaging of patients with inflammatory and autoimmune diseases must provide a comprehensive view of the body, enabling the whole-body mapping of systemic involvement. It should identify key cellular players in the pathology, involving both innate immunity (dendritic cells, macrophages), adaptive immunity (lymphocytes), and microenvironmental cells (stromal cells, tissue cells). As a highly sensitive imaging tool with vectorized molecular probe capabilities, PET/CT can be of high relevance in the management of numerous inflammatory and autoimmune diseases. Relying on key molecular concepts of immunity, the clinical usefulness of FDG-PET/CT in several relevant inflammatory and immune-inflammatory conditions, validated or emerging, will be discussed in this review, together with radiolabeled probe perspectives.
Section snippetsIntroduction: Concept of Inflammation and ImmunityChronic immune diseases mainly including autoimmune and inflammatory diseases, can affect more than 10% of the general population. Recent evidence suggests that their incidence is on the rise.1 The classification of autoimmune diseases distinguishes between systemic autoimmune diseases, such as lupus, Sjögren's syndrome, and scleroderma, and organ-specific autoimmune diseases, including autoimmune thyroiditis and type 1 diabetes. Besides, chronic inflammatory disorders may include giant cell
ConclusionPET imaging provides unparallel capabilities to map and quantify inflammatory and immune-mediated conditions at the whole-body level. FDG PET/CT has become the imaging modality of choice in the work-up of patients with FUO, by identifying the potential cause, localizing sites for further evaluation, and guiding further management. In cardiometabolic syndrome, FDG PET facilitates detailed molecular imaging of active atherosclerotic processes, offering insights into visceral abdominal fat tissue
Declaration of Competing InterestThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Ethical StatementThis review article does not deal with experiments nor with individual patient data and does not require IRB approval.
References (164)M Pean de Ponfilly-Sotier et al.Use of 18F FDG PET-CT to discriminate polymyalgia rheumatica and atypical spondylarthritis in clinical practiceJoint Bone Spine
(2022)
V Deshpande et al.Consensus statement on the pathology of IgG4-related diseaseMod Pathol
(2012)
A Vaglio et al.Retroperitoneal fibrosisLancet
(2006)
H Matsubayashi et al.Usefulness of positron emission tomography in the evaluation of distribution and activity of systemic lesions associated with autoimmune pancreatitisPancreatology
(2009)
K Nakatani et al.Utility of FDG PET/CT in IgG4-related systemic diseaseClin Radiol
(2012)
EE Carter et al.The global burden of SLE: prevalence, health disparities and socioeconomic impactNat Rev Rheumatol
(2016)
G Grateau et al.How should we approach classification of autoinflammatory diseases?Nat Rev Rheumatol
(2013)
JN Hoes et al.Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritisNat Rev Rheumatol
(2010)
W-T Ma et al.The role of monocytes and macrophages in autoimmune diseases: A comprehensive reviewFront Immunol
(2019)
G Nocturne et al.B cells in the pathogenesis of primary Sjögren syndromeNat Rev Rheumatol
(2018)
C Pitzalis et al.Ectopic lymphoid-like structures in infection, cancer and autoimmunityNat Rev Immunol
(2014)
CP Bleeker-Rovers et al.A prospective multicenter study on fever of unknown origin: The yield of a structured diagnostic protocolMedicine (Baltimore)
(2007)
JP Pijl et al.Role of FDG-PET/CT in children with fever of unknown originEur J Nucl Med Mol Imaging
(2020)
J Holubar et al.Diagnostic performance of 18 F-FDG-PET/CT in inflammation of unknown origin: A clinical series of 317 patientsJ Intern Med
(2022)
H Balink et al.Diagnostic utility of (18)F-FDG PET/CT in inflammation of unknown originClin Nucl Med
(2014)
AM García-Vicente et al.Do clinical and laboratory variables have any impact on the diagnostic performance of 18F-FDG PET/CT in patients with fever of unknown origin?Ann Nucl Med
(2018)
FL Besson et al.Contribution of 18F-FDG PET in the diagnostic assessment of fever of unknown origin (FUO): A stratification-based meta-analysisEur J Nucl Med Mol Imaging
(2016)
KS Simons et al.F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infectionIntensive Care Med
(2010)
JP Pijl et al.FDG-PET/CT in intensive care patients with bloodstream infectionCrit Care
(2021)
AWJM Glaudemans et al.Expert opinions in nuclear medicine: Finding the “holy grail” in infection imagingFront Med (Lausanne)
(2023)
E Kassi et al.Atherosclerotic and cardio-metabolic diseases: From molecular basis to therapeutic advancesIJMS
(2023)
P Libby et al.Inflammation and atherosclerosisCirculation
(2002)
J Bucerius et al.Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosisEur J Nucl Med Mol Imaging
(2016)
M Reijrink et al.[18F]FDG uptake in adipose tissue is not related to inflammation in type 2 diabetes mellitusMol Imaging Biol
(2021)
J Bucerius et al.Arterial and fat tissue inflammation are highly correlated: A prospective 18F-FDG PET/CT studyEur J Nucl Med Mol Imaging
(2014)
AM Sammartino et al.Vascular inflammation and cardiovascular disease: Review about the role of PET imagingInt J Cardiovasc Imaging
(2023)
M Marnane et al.Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrenceAnn Neurol
(2012)
JJ Fuster et al.Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular diseaseCirc Res
(2016)
A Tchernof et al.Pathophysiology of human visceral obesity: An updatePhysiol Rev
(2013)
J-P Després et al.Abdominal obesity and metabolic syndromeNature
(2006)
K Pahk et al.Characterization of glucose uptake metabolism in visceral fat by 18 F-FDG PET/CT reflects inflammatory status in metabolic syndromePLoS One
(2020)
K Pahk et al.Association of glucose uptake of visceral fat and acute myocardial infarction: A pilot 18F-FDG PET/CT studyCardiovasc Diabetol
(2020)
RHJA Slart et al.Long axial field of view PET scanners: A road map to implementation and new possibilitiesEur J Nucl Med Mol Imaging
(2021)
F Jamar et al.EANM/SNMMI Guideline for18 F-FDG Use in Inflammation and InfectionJ Nucl Med
(2013)
GG Hunder et al.The American College of Rheumatology 1990 criteria for the classification of giant cell arteritisArthritis Rheum
(1990)
D Blockmans et al.New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomographyRheumatology (Oxford)
(1999)
KB Gribbons et al.Patterns of arterial disease in Takayasu arteritis and giant cell arteritisArthritis Care Res
(2020)
FL Besson et al.Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A systematic review and meta-analysisEur J Nucl Med Mol Imaging
(2011)
M Soussan et al.Management of large-vessel vasculitis with FDG-PET: A systematic literature review and meta-analysisMedicine (Baltimore)
(2015)
P Bosch et al.Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendationsRMD Open
(2023)
View full text© 2023 Elsevier Inc. All rights reserved.
Comments (0)